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PrognosisColorectal cancer, a leading cause of mortality worldwide, is a multistep disorder that results from the alteration
of genetic and epigenetic mechanisms under contextual inﬂuence. Epigenetic aberrations, including DNA
methylation, histone modiﬁcations, chromatin remodeling and non-coding RNAs, affect every aspect of tumor
development from initiation to metastasis. Cancer stem cell promotion is also included in the wide spectrum
of epigenetic dysregulations. Elucidation of this complex crosstalk network may offer new insights in the molec-
ular interactions involved in the pathogenesis of colorectal carcinogenesis. In the era of translational medicine
new horizons are opened for the pursuit of personalized therapeutic approaches and the development of novel
and accurate diagnostic, prognostic and therapy-assessment markers. This review discusses the implications of
epigenetic mechanisms in tumor biology and their applications “from bench to bedside”.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) is a leading cause ofmorbidity andmortality
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ou).disorder that results from the accumulation of genetic and epigenetic
aberrations under microenvironmental inﬂuence. Abnormalities in
key regulatory genes and pathways, including p53,Wnt, DNAmismatch
repair genes and Ras drive the progression of the disease from benign
adenoma, to carcinoma and eventually to metastatic disease [2]. Geno-
mic instability is pivotal for CRC development and is attributed to
chromosomal instability (CIN) and microsatellite instability (MSI).
Such dysregulations may cause sporadic or hereditary syndromes of
CRC. CIN is a major defect found in cases of CRC (about 80%), which
leads to gain or loss of whole chromosomes or chromosomal parts
and the dysfunction of crucial genes such as Ras, adenomatous
polyposis coli (APC) and p53. InMSI tumors a defect inmismatch repair
genes is observed [3–5].
Epigenetic regulation refers to heritable and possibly reversible
changes in the phenotypic expression of the genome, which alter gene
expression without affecting DNA sequence [6,7]. In the wide gamut
of epigenetic mechanisms are included, DNA methylation, histone
modiﬁcations, chromatin remodelers and non-coding RNAs, which are
implicated in the activation of oncogenes, the loss of function of tumor
suppressors and the loss of imprinting [4,7,8]. By ﬁne-tuning the acces-
sibility of DNA, epigenetics orchestrate various physiological procedures
(transcription, replication, repair) from developmental to differentiated
stages and possess a pivotal role in the process of tumorigenesis.
Genetic and epigenetic aberrations are involved in a complex network
and can both predispose to or cause the development of each other
(Fig. 1) [5,7,9]. The understanding of these mechanisms may contribute
to the optimization of diagnostic and prognostic systems as well as the
generation of novel and targeted therapeutic approaches.
Fig. 1. Schematic representation of the mechanisms that lead to colorectal cancer. Genetic and epigenetic aberrations are involved in a complex network, responsible for modulations in
gene expression patterns. Activation of oncogenes and/or silencing of tumor suppressors promote colorectal carcinogenesis.
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2.1. DNA hypomethylation
In normal cells DNA methylation plays a signiﬁcant role in securing
DNA stability through transcriptional silencing of genetic elements
such as repetitive nucleotide sequences and endogenous transponsons.
Furthermore DNA methylation reassures gene imprinting, transcrip-
tional blockage of the genes on the inactive X-chromosome and normal
growth, development and differentiation, while it also contributes in
homeostasis maintenance and genomic adaption in response to envi-
ronmental stimuli [10]. Global genomic hypomethylation, characterized
by the gradual and genome wide depletion of methylated cytosine
bases (5-methyl-cytosine) in cancer cells, is observed even in early
stages across CRC development and progression [3]. DNA hypomethyla-
tion represents an epigenetic alteration that gathers in an age-dependent
manner, possibly due to gradual acquisition of errors during DNAmeth-
ylation mediated by constitutive methyltransferases and correlates to
genomic damage. Demethylation of pericentromeric regions seems to
induce DNA recombination errors and inaccurate chromosome duplica-
tion [11]. More precisely global DNA hypomethylation mainly takes
place on cytosine guanine (CpG) dinucleotides within mobile and
repetitive genetic elements such as satellite DNA sequences (including
the aforementioned centromeres), long interspersed nuclear element
(LINE) repeats and retrotransponsons [5]. This pattern of hypomethyla-
tion could be involved in tumorigenesis through the increased accumu-
lation of chromosome breakage and the induction of expression of
formerly silenced genetic elements (e.g. retrotransponsons) resulting
in the disorganization of the normal nucleotide sequence and the im-
pairment of chromosomal stability. The above could explain why DNA
hypomethylation is mostly seen in CIN CRCs [3]. LINE-1 is frequently
hypomethylated in CRC, exhibits a relatively stable demethylation
state across CRC progression, even at early stages. Its enhanced activa-
tion through hypomethylation is associated with increased genomic
instability and enhanced cancer ability to penetrate surrounding tissues
and metastasize. [12,13]. Apart from genomic instability, another
mechanism of colorectal carcinogenesis development and promotion,attributed to hypomethylation, is oncogene positive transcriptional
regulation [8,10]. The events that propel global demethylation are not
yet fully elucidated. APCmutation, which is a driving event in colorectal
tumorigenesis, seems however to be able to control DNA methyltrans-
ferase (DNMT) expression and activity, which concomitantly results in
demethylation of a number of genes and forces intestinal cells to remain
in a more undifferentiated and progenitor-like state. Accordingly,
genetic and epigenetic interactions constitute a possible mechanism
involved in tumor initiation and progression [14].
Loss of imprinting (LOI) is deﬁned as the impairment of the epige-
netically regulated in a parent-of-origin manner, monoallelic, selec-
tive expression of certain genes, which could lead to developmental
abnormalities. Imprinted genes also frequently (about 40% of CRC
cases) undergo genome-wide hypomethylation early in the process of
colorectal tumorigenesis [8,15]. In CRC tissues and cell lines, LOI of the
insulin-like growth factor-2 gene (IGF2), leads to aberrant expression
of the normally epigenetically-repressed maternally-inherited copy.
Upregulation of the encoded protein levels, enhances the activation of
IGF1 receptor (IGF1R) and its downstream signaling pathways, including
phosphatidylinositide 3-kinase (PI3K)/Akt and GRB2/Ras/extracellular
signal-regulated kinase (ERK) [5,15].
2.2. DNA hypermethylation
DNAmethylation in humans takes place on the ﬁfth position carbon
of the pyrimidine ring of cytosines located in CpGdinucleotides. This pro-
cess is mediated by three DNA methyltransferases (DNMT1, DNMT3A
and DNMT3B), which require the methyl donor-cofactor S-adenosyl-
methionide (SAM) in order to add a methyl-group to cytosine residues
[13]. CpG dinucleotides are unequally spread throughout the genome,
gathered in small DNA stretches called CpG islands (CGIs). These CpG-
rich regions are mostly present close to the promoter region of almost
50% of all human genes [3]. While the vast majority of CpG dinucleotides
found in DNA sequences between genes are methylated, CpG islands are
generally unmethylated in normal colonic epithelial cells [4,13]. There is
an established association between aberrant DNA methylation of CGIs
located close to gene promoter region and abnormal inhibition of gene
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regulator and DNA-repair genes transcriptional silencing (Fig. 2) [4,5].
Aberrant CGI promoter hypermethylation results in gene silencing
through the orchestration of the “enrollment” and binding of methyl-
CpGbinding proteins that in turn affect the recruitment of transcriptional
corepressors which confer transcriptional suppression via histone modi-
ﬁcations [16,17].
APC, Cadherin-1 (CDH1), runt-related transcription factor 3 (RUNX3),
mutL homolog 1 (MLH1), O-6-methylguanine-DNA methyltransferase
(MGMT), cyclin-dependent kinase inhibitor 2A (CDKN2A), and RASSF1A
are among the genes frequently determined to undergo CGI-promoter
hypermethylation-mediated inactivation in CRC [18,19]. APC promoter
hypermethylation has been shown to correlate with metastatic CRC,
while inactivation due to promoter hypermethylation of the mismatch-
repair gene MLH1 is often observed in sporadic CRC with MSI [5,8]. In
MSI CRC patients, apart from tumor tissues, MLH1 methylation has
been also detected in adjacent morphologically “health-appearing”
colonic epithelial tissues. Furthermore, MGMT, another DNA-repair
gene, frequently undergoes biallelic promoter-hypermethylation asso-
ciated silencing in CRC, which in turn seems to favor mutations in
cancer-related genes (e.g. p53 and kRAS). MGMT has been also found
to exhibit promoter methylation in precancerous polyps [20]. Simi-
larly to hypomethylation, CGI promoter hypermethylation of some
genes seems to accumulate in an age-dependent manner in normalFig. 2. Proposedmodel of epigeneticmodiﬁcations in active and silenced genes. Epigeneticsmod
acterized by CpG islandhypermethylation,mediated byDNMTs, the removal of acetyl-groups by
of the PRC2 complex. All these events raise chromatin compactness. Active genes are characteriz
presence of active histonemethylationmarks,which promote chromatin loosening. In general, H
by H3K4me2 or H3K4me3. Chromatin remodelers can be related with both active and represse
HDACs and HDMTs. Pink cylinders represent nucleosomes, solid arrows represent addition and
transferase; EZH2, histone methyltransferase enhancer of Zeste 2; H, histone; HAT, histone ac
methyltransferase; K, lysine residue; me, methylation; PRC, polycomb repressive complex.colonic epithelium (e.g. MLH1) and in tandem to the “premalignant to
malignant” progressive CRC transformation (e.g. MGMT) [3,21]. The
above suggest that promoter hypermethylation of certain genes, includ-
ing DNA-repair genes, may precede tumor formation and its detection in
apparently normal colonic epithelium, in premalignant lesions that occur
early in CRC development as well as in other body samples (e.g. stool
and plasma) could provide promising diagnostic biomarkers. These bio-
markers could nominate a subject of patients at great risk for CRC who
may beneﬁt from closer follow-up with gold-standard diagnostic
methods and more intensive CRC preventive interventions, also by tak-
ing advantage of the reversible nature of epigenetic alteration [13].
According to a genome-wide methylation analysis in 24 CRC and
matched normal tissues, among the genes whose promoters were
found to be hypermethylated several genes did not exhibit any known
signiﬁcant correlation with disease clinicopathological features, sug-
gesting that aberrant gene methylation may not always inﬂuence can-
cer cell fate [22]. Nevertheless this fact does not preclude their usage
as diagnostic and prognostic biomarkers [10].
Dependent on the aberrant hypermethylation of a large number of
gene promoters CRC can be distinguished into two subclasses, each
with distinctive genetic and clinicopathologic characteristics: CpG
island methylator phenotype (CIMP) positive (+) and CIMP negative
(−) CRCs. More precisely CIMP+ CRCs are mostly met in high-grade
mucinous carcinomas, located in proximal colon, with MSI andify gene expression patterns by controlling chromatin condensation. Silent genes are char-
HDACs andmodulations inhistonemethylationmarks byHDMTs andHMTs, such as EZH2
edby the absence of CpG islandmethylation, the addition of acetyl-groups byHATs and the
3K9me3 andH3K27me3 are relatedwith gene repression,while active genes are enriched
d DNA regions through the regulation of nucleosomal architecture and the recruitment of
dashed arrows represent removal. Abbreviations: A, acetyl-groups; DNMT, DNA methyl-
etyltransferases; HDAC, histone deacetylase; HDMT, histone demethylases; HMT, histone
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tumors are most frequently associated with older ages and the female
gender [3,4]. Despite the established relationship between BRAF
mutation and CIMP+ occurrence, it should be further enlightened in
what way and to what extent this mutation could drive and enhance
CIMP+ [4,23]. Apart from the possible implication of BRAF mutation
in promoting aberrant hypermethylation of CpG-rich gene promoters,
another potent cause that could render CGI promoter regions prone to
methylation in CRC cells, is the increased number of polycomb repres-
sive complex (PRC) 2marks in human embryonic stemcells that is pres-
ent since the normal early development. It has been shown that in CRC
cells, hypermethylated genes, are not only highly pre-marked by PRC2
components, but also exhibit elements within their genome that are
able to recruit PRC2. PRC2 could predispose to gene hypermethylation
by directly or indirectly interacting with DNMTs [3]. Additionally,
these methylation predisposed regions seem to be deprived of some
transcription factor binding sites, such as Sp1, yin yang 1 (YY1) and
nuclear respiratory factor 1 (NRF1), which are regarded as methylation
inhibitors in cancer cells [14].
3. Histone modiﬁcations
Histone (H)modiﬁcations are included in the spectrum of transcrip-
tional regulation by coordinating DNA accessibility through acetyla-
tion, methylation, phosphorylation, ubiquitylation, summoylation, ADP
ribosylation, deamination and proline isomerization of speciﬁc core his-
tone (H2A, H2B, H3, H4) residues [7,8]. Post-translational modiﬁcations
of histones are involved in the integration center of transcriptional
control by ﬁne-tuning the balance between the active (euchromatin)
and the inactive (heterochromatin) states of chromatin [7]. Apart
from their contribution in various physiological processes, histone
modiﬁcations are responsible for the aberrant genetic and epigenetic
proﬁles, which occur in numerous types of solid (prostate, breast,
colorectal, lung) and hematological malignancies [7,9]. The established
role of epigenetics in CRC pathogenesis offers an alternative pathway to
elucidate the deep secrets of cancer development (Fig. 2).
Histone acetylation and methylation are the most widely studied
aberrations of histone proﬁles in CRC. The residue that is modiﬁed, the
location of the histone and the category of alteration deﬁne the outcome
[5]. The post-translational addition of acetyl-groups interferes in the
electrostatic binding between the negatively charged DNAand histones,
thus mediating chromatin loosening and facilitating transition to active
states. Acetylation and deacetylation of lysine residues (K) at histone
tails is achieved via histone acetyltransferases (HATs) and histone
deacetylases (HDACs) respectively [7]. Histone methylation occurs at
lysine, arginine and histidine residues, with lysine being the most com-
mon site however. Histonemethyltransferases (HMTs) and demethylases
(HDMTs) specify histone methylation proﬁles [7,24]. Methylation (me)
does not change the electrostatic properties of the structure and is relat-
ed with both active and silenced DNA region. Lysine residues can be
mono-, di- or tri-methylated [6,7]. Active DNA regions are marked
with HEK4me2- or me3 and/or H3, H4 acetylation, while H3K9me3
or H3K27me3 and the absence of acetylation characterize repressed
regions [5,6].
3.1. Histone acetylation
HATs are divided into two basic categories, namely: the nuclear type
A HATs, and the cytoplasmic type B HATs, which acetylate free histones
[25]. Their role in CRC is complicated and they are implicated in com-
plex cross-talk networks affecting numerous signaling pathways.
CREB-binding protein (CBP)/p300 and their associated factor (PCAF)
facilitate the effects of β-catenin through acetylation [26]. Strikingly,
the role of p300 in CRC has not yet been elucidated as its overexpression
has been associated with advanced tumor stages and poor clinicaloutcome [27], while other research groups have linked p300 expression
with increased survival [28].
The family of HDACs consists of 18members and it is subdivided into
four classes: I (1–3, 8), II (4–7, 9, 10), III (sirtuins 1–7) and IV (11). Clas-
ses I, II and IV comprise the classical family, which are Zn-dependent,
while class III is NAD+-dependent [29]. HDACs aremembers of multiple
co-repressor complexes [30]. HDAC2 upregulation is implicated in the
early and vital steps of CRC. Additionally, HDAC1–3, 5, and HDAC7
have also been reported to be upregulated in CRC [31]. Evidence from
various CRC cell lines implicated class I and III HDACs in the down-
regulation of tumor suppressor genes such as caudal type homeobox-
1 (CDX1), which belong in the Wnt signaling cascade [32]. Apart from
histones, HDACs interact with various other proteins. It has been
shown that HDAC3 maintains the DNA-repair gene CtBP-interacting
protein (CtIP) in its functional deacetylated state [33]. Sirtuin-3 could
act as a tumor suppressor through the reduction of oxidative stress via
the regulation of hypoxia inducible factor (HIF) pathway, at least in
part. Knock-down of sirtuin 3 in the CRC cell line HCT116 led to
increased proliferation, while overexpression inhibited carcinogenesis
[34].3.2. Histone methylation
Histone methylation is a dynamic and ﬂexible procedure. A con-
served SET domain, responsible for the enzymatic function can be
found in each HMT. In cooperation with HMTs, HDMTs modulate his-
tone methylation proﬁles [7]. Large co-repressor complexes harbor
HDMTs [30].
Lysine speciﬁc demethylase 1 (LSD1) is an HDMT, which demethylates
H3K4me2 and H3K9 and has been associated with various cellular
mechanisms including proliferation and differentiation. Apart from
alteration of the histone code, LSD1 interacts with various molecules
such as p53 and DNMT1 and is linked with malignant transformation.
LSD1 seems to potentiate proliferation, invasiveness and metastatic
potential of CRC cells as it has been depicted by knockout experiments
on cell-lines and mouse xenograft models [35,36]. LSD1 has been posi-
tively correlated with TNM stage, lymph node inﬁltration and metasta-
tic disease in CRC patients [37].
Recent experimental data reveal novel wirings between HMTs and
key regulatory signaling pathways. A speciﬁc HMT-complex mediates
the suppressive effects of Notch on genes downstream ofWnt, whereas
mixed lineage leukemia-4 (MLL4) regulates the expression of cell cycle
and angiogenesis factors in CRC cells [38,39]. Immunohistochemical
studies have correlated the expression patterns of certain histonemeth-
ylation marks (e.g. H3K9me2, H3K9m3, H3K27me2) with various
clinicopathological parameters in CRC patient, including lymph node
inﬁltration and distant metastasis [40–42].
Moreover, the Polycomb-group protein family, which consists of
the complexes PRC1 and PRC2, mediates epigenetic silencing via his-
tone methylation. PRC1 binds at H3K27me3 and possesses histone-
ubiquitylation abilities. The histone methyltransferase enhancer of
Zeste 2 (EZH2) is the central unit of PRC2, responsible for H3K27me3.
PRC1 and PRC2may cooperate for gene repression or act in an indepen-
dent manner [43,44]. Polycomb proteins coordinate crucial develop-
mental steps and their malfunction is often observed in various
malignancies. In vitro evidence from CRC cells indicate the involvement
of EZH2 in tumor proliferation and growth [45]. PRC1 and PRC2 com-
plexes are speculated in metastasis through their ability to repress
E-cadherin via B lymphoma Mo-MLV insertion region 1 homolog
(Bmi1) and EZH2 respectively [46]. Alternatively, ERK, Akt and activator
protein 1 (AP-1) seem to enable EZH2 expression,which in turn in facil-
itates EMT through the down-regulation of integrin alpha2 [47]. Mem-
bers of the polycomb group family, such as Bmi1, have been found
elevated in CRC patients and have been correlatedwith advanced stages
and aggressive types of carcinomas [48].
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Apart from the widely studied histone modiﬁcations, ubiquitination
may serve as an alternative mechanism of gene regulation in CRC. His-
tone ubiquitination can be associated with both gene silencing and
activation. It has been shown that an H2B ubiquitin ligase is mutated
in various solid tumors including CRC, whereas an H2B deubiquitinase
has been reported to be overexpressed in colorectal and breast cancer
[49]. Recently, loss of H2B monoubiquitination has been linked with
the abnormal glucose metabolism of cancer cells, which permits surviv-
al in adverse conditions [50]. In vitro and in vivo data point out that
histone 2A ubiquitination, mediated by the PRC1 complex member
Bmi1, is actively involved in the proliferation of CRC cells [51].4. Chromatin remodeling complexes
Chromatin-remodeling complexes, by forming a dynamic equilibri-
um (activation/repression), orchestrate a wide range of physiological
processes including, proliferation, self-renewal and differentiation
[30]. By consuming ATP-derived energy, these complexes manipulate
nucleosomal architecture through the dynamic mobilization (insertion/
eviction) of nucleosomes as well as the conﬁguration of nucleosomal
DNA and histone-octamers [7,9,52]. Additionally, chromatin-remodelers,
which can function as tumor suppressors or promoters depending on
contextual signaling, recruit HDACs, HDMTs and numerous auxiliary
proteins in order to construct large scaffolds, and participate in com-
plex cross-talk networks with numerous transcription factors [30].
Overexpression ormutated formsof severalmembers of the remodeling
machinery have been identiﬁed in a broad range of hematological and
solid malignancies (Fig. 2) [7,9,30,52].
Nucleosomal insertion in the promoter CpG island region may
facilitate epigenetic gene silencing through heritable modiﬁcations in
chromatin conformation, as in the case of MLH1 [53]. Similarly, distant
Wnt-related responsive enhancers may reach and up-regulate c-Myc,
a pivotal coordinator of proliferation and apoptosis in CRC, through
the generation of large chromosomal loops [54]. Recent experimental
data link the upregulation of vascular endothelial growth factor
(VEGF) by peroxisome proliferator activated receptor δ (PPAR-δ)
through a mechanism that involves β-catenin-mediated chromatin
looping [55].
SWI/SNF complex seems to be involved in multiple aspects of CRC
development and progression. For instance, BRG1 is implicated in the
promotion of metastasis through a mechanism involving the down-
regulation of E-cadherin [56]. Inactivating mutations of several SWI/
SNF members is a frequent event in CRC patients (especially with
MSI), including ARID1A and SMARCC2 [57,58].
Furthermore, another chromatin-remodeler, nucleosome remodel-
ing and histone deacetylase (NuRD), determines the fate of various
signaling cataracts [30]. NuRD is responsible, at least in part, for the ab-
rogation of the transcriptional activity of AP-1 transcription factor. AP-1
possesses a pivotal role in the orchestration of intestinal proliferation
and the promotion of tumorigenesis [59]. NuRD however is also in-
volved in the silencing of tumor suppressor genes, such as negative reg-
ulators of Wnt, often in synergy with DNMTs [60]. In accordance to this
data, immunohistochemical analysis of surgically resected colorectal
tumors correlated the positive expression of NuRD members with
decreased overall survival and poor clinical outcome [61].
Recent data from mouse models reveal that members of the
chromatin-remodeling machinery, such as the HAT Tip60 and the
ATPase p400, modulate the actions of Wnt-cascade. Tip60 is implicated
in DNA-damage response, exerts anti-proliferative effects and represses
the Wnt-pathway. On the other hand p400 exerts counteracting
effects by up-regulating Wnt and inhibiting Tip60. In CRC, the ratio
of Tip60/p400 is unbalanced in favor of p400 and promotesWnt activity
and carcinogenesis [26].5. Non-coding RNAs
MicroRNAs (miRNA, miR) constitute a complementary mechanism
of gene expression control involved in a multi-level interplay with the
epigenetic machinery by both regulating epigenetic alterations and
being regulated by them [62]. This subset of short endogenous non-
coding RNAs (≈22 nucleotides) post transcriptionally downregulates
gene expression through binding to a complementary site that resides
on the 3′-untranslated region of target mRNAs. Upon binding, miRNAs
incorporated into an RNA-induced silencing complex induce cleavage or
translational repression of target-mRNAs [8,63]. Aberrations of miRNA
expression are often observed in CRC and seem to play a signiﬁcant role
in tumor development and progression, which comes in accordance
with the suggestion that miRNAs exert oncogenic or tumor-suppressor
effect. It has been shown their behavioral pattern could sometimes be
modulated dependent on tumor-derived microenvironmental stimuli.
For example, miR-145 displayed anti-tumor promoting activity in prima-
ry CRC, while in advanced disseminated disease enhanced tumor promo-
tion [64,65]. However, miRNA implication in virtually every important
aspect of the multistep colorectal carcinogenesis and their clinicopatho-
logical impact have already been proved and several examples are avail-
able. Tumor suppressor genes, such as phosphatase and tensin homolog
(PTEN) and topomyosin 1 have been identiﬁed as targets of miR-21 and
thus its upregulation in CRC results in reduced expression levels and
activity of those genes. It has also been shown that miR-21 promoter
region carries a binding loci for STAT3 transcription factor, whose upreg-
ulation has been suggested to occur in an age-related manner and in car-
cinogenesis, triggered by sustained IL6 signaling [8,66]. Furthermore,
miR-21 is found abundantly expressed in chemo-resistant CRC cells.
Induced suppression of miR-21 promoted both differentiation, as indi-
cated by cytokeratin 20 upregulation, and sensitization to chemothera-
peutic regimens [67]. miR-135 has been also considered to exert onco-
promoting activity in colorectal pre-malignant and malignant lesions,
by downregulating expression levels and activity of APC. On the con-
trary, induced activation of APC in CRC cells led to miR-122a positive-
regulation, which has been shown to mediate APC anti-tumor effects.
Thus the presence of a “functional intersection” between miR-135,
APC andmiR-122a in tumor cell fate control could be hypothesized [66].
On the other hand, miR-34 family members and miR-137 act
as tumor-suppressors and are often downregulated in CRC [68,69].
miR-34 family members (miR-34a, b, c) are positively regulated by
p53. Transfection of miR-34a into CRC cells led to inhibition of cell
proliferation-rate and apoptosis induction, at least partially by amplify-
ing p53 signaling cascade. It has also been reported thatmiR-34a targets
Sirtuin-1, which in turn induces p53 transcriptional upregulation. The
above suggest the existence of a positive feedback loop between p53
and miR-34a, and that miR-34a could partly mediate p53 tumor-
suppressive function [8,66,69]. Additionally, it seems thatmiR-34 family
members are part of the “reciprocal” constitutive interplay between
miRNAs and the enzymatic components of the epigenetic machinery,
as CGI promoter hypermethylation of miR-34b/c takes place in the
vast majority of primary CRCs [69,70]. In the same context, miRNAs
with tumor-suppressing functions such as miR-1-1, miR-9-1, miR-
129-2 and miR-124 family members have been reported to undergo
CGI promoter hypermethylation-induced silencing and this irregular
methylation often occurs at an early stage during CRC development
[69,71].What ismore,miRNAdysregulation can further induce aberrant
activity of the enzymatic components of the epigenetic machinery. As
an example, DNMT3A has been identiﬁed as miR-143 target, and thus
miR-143 suppression in CRC results in DNMT3A increased expression
levels [66,69]. miR-140 and miR-449 have been shown to exert their
tumor-suppressive effects by targeting and downregulating HDAC4
and HDAC1 respectively. Thus miR-140 and miR-449 downregulation
in CRC may be responsible for aberrant histone acetylation induction
[64,70]. Furthermore, miR-627 enforces the anti-tumor function of
vitamin D by directly downregulating, an histone demethylase, levels
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and migration. miR-200 family members for example, suppress EMT
and tumor cell metastatic potential by directly downregulating E-
cadherin repressors, such as zinc ﬁnger E-box-binding homeobox
(ZEB) 1 and 2. ZEB1 seems also to negatively regulate the expression
levels of certain miR-200 family members, indicating the existence
of an interactive network between ZEB1 and miR-200 family, in the
control of CRC dissemination [64,66]. Apart from miRNAs, increased
expression of long intergenic non-coding (linc) RNAs, such as lincRNA-
p21 and hox transcript antisense intergenic RNA (HOTAIR), has been
correlated to advanced CRC stage and enhanced metastatic potential of
CRC cells. Linc-RNAs probably also interact with the epigenetic machin-
ery, namely HOTAIR, has been shown to exert its oncogenic activity in
association with PRC2 [6,73].
Taken together, these ﬁndings highlight the importance of miRNAs
in association with epigenetics in CRC carcinogenesis.
6. Long range epigenetic silencing
Epigenetic modiﬁcations do not refer only in single and local gene
control, but may also affect larger chromosomal regions, where numer-
ous genes are embedded. The term long range epigenetic silencing
(LRES) was established after the discovery of a silenced large region
at chromosome 2q14.2, which contained multiple tumor-suppressor
genes with promoter CpG hypermethylation and H3K9me2. Similarly,
in MSI-H CRCs LRES has been observed for a 3p22 locus, where most
of the harbored genes, including MLH1, were reported to undergo tran-
scriptional repression mainly due to promoter hypermethylation [5].
Recent studies suggest that LRESmay span in the deregulation of multi-
ple genes that control crucial cellular processes. The transcription factor
Ikaros, which controls differentiation, as well as a large region at 5q31,
which contains several members of the tumor suppressor family of
protocadherins are under LRES [74,75]. The exact mechanism and the
sequence of events that drive LRES remain to be elucidated [5].
7. Colon cancer stem cells and epigenetics
The newly introduced cancer stem cell (CSC) model approaches
carcinogenesis froma different point of view. Notably, CSCs are regarded
as the “top-notch” players in cancer, responsible for its propagation,
heterogeneity and metastasis [8]. The characteristic feature of CSCs to
switch various genes between “on and off” positions according to the
need for proliferation or differentiation suggest the existence of an
epigenetic mechanism [76,77]. Indeed, a wide gamut of proposed CSC
markers such as CD133, CD44 and aldehyde dehydrogenase-1 (ALDH1)
have been reported to be epigenetically reprogrammed in hematologic
and solid malignancies, including CRC, whereas Bmi1, a member of the
PRC1 complex, is a putative marker of both normal intestinal and cancer
stem cells. Moreover epigenetics modulate the activity of signaling
circuitries (Wnt, Hedgehog and Notch), which coordinate CSC mainte-
nance and ampliﬁcation [76,77]. The Wnt pathway seems to function
as an indirect activator of Bmi1, possibly through the c-myc oncogene.
Additionally, kruppel-like factor 4 (KLF4), which regulates the prolifera-
tion and differentiation of intestinal SCs, directly blocks Bmi1. The exact
role of KLF4 in CSC biology however needs to be elucidated [51].
8. Epigenetic modiﬁcations: biomarker potential
CRC remains a global burden in world health and economy despite
having a 90% of 5 year survival when detected and treated early [1,4].
It is therefore essential to develop robust techniques, which will
not only aid current diagnostic procedures but will also permit non-
invasive and more accurate screening, diagnosis, follow-up and response
to therapy of cancer patients [4,5]. In this direction, epigenetics seem to be
very promising candidates.DNAmethylation biomarkers, collectively referring to genes that are
abnormally repressed due to promoter methylation in CRC, are appeal-
ing targets as they appear early in carcinogenesis. Recently, novel DNA
methylation biomarker assays passed clinical trials and became com-
mercially available. ColoVantage® is a blood based test, which detects
the presence of methylated septin 9 (SEPT9). The assay achieves an
overall sensitivity of 90%. Other clinically available methods utilizing
SEPT9 methylation are Epi proColon® 1.0 and Abbott RealTime mS9.
Additionally, ColoSureTM is a commercially available fecal-based assay
that operates based on the methylation of the vimentin gene. This test
should be used in combination with colonoscopy and has a reported
sensitivity ranging from 38 to 88% [78,79]. Themajority of DNAmethyl-
ation biomarkers are not yet clinically available. Numerous fecal-based
(e.g. NDRG4, GATA4) and blood-based (e.g. RUNX3, SDC2, NEUROG1)
candidate biomarkers are being extensively tested in laboratory and
clinical trials with encouraging results [13,78,79].
miRs have been also characterized as promisingputative biomarkers.
A wide variety of miRs seems to function as tumor-suppressors such as
miR-149, which are epigenetically silenced due to hypermethylation in
CRC [78]. OncogenicmiRs carry also useful clinical information, as in the
case of miR21which has been associated with metastasis and poor sur-
vival [13]. On the contrary, histonemodiﬁcations are not in the spotlight
of the research community, regarding their utility as biomarkers. Sever-
al studies have correlated the presence of histone marks or histone
modifying enzymes with various clinicopathological characteristics in
patients with CRC [13]. Future studies are needed to elucidate the bio-
marker potential of histone modiﬁcation.
9. Therapeutic implications
The era of translational medicine dictates the future of therapeutic
approaches in cancer. Treatment modalities should be tailored accord-
ing to the concept of personalized medicine. Targeting of epigenetic
modiﬁcations offers an additional weapon to our therapeutic arsenal
in combination with conventional measures. The plethora of in vitro
and in vivo evidence suggesting that epigenetics exert a fundamental
role in CRC, as well as their reversible nature determine the rationale
behind this approach. Additionally, epigenetics are involved in the acqui-
sition of drug resistance to conventional agents such as 5-ﬂuorouracil,
irinotecan and oxaliplatin. Therefore combined therapies may reverse
resistance and sensitize previously refractory tumors, whereas the
simultaneous administration of agents modulating DNA methylation
and histone acetylation patterns may produce enhanced synergistic
anti-cancer efﬁcacy [80–82]. DNMT and HDAC inhibitors (DNMTi,
HDACi) administration has been extensively investigated in both
preclinical and clinical level. Most clinical studies were performed on
heavily pretreated advanced stage patients and sought to determine
maximum tolerated dose, pharmacokinetics, pharmacodynamics, pos-
sible adverse reactions and anti-cancer potential. Data from studies
however are not so encouraging [80]. Major clinical studies that have
been conducted so far are summarized in Table 1.
9.1. Synthetic compounds
9.1.1. DNA methylation inhibitors
DNAmethylation inhibitors are categorized into nucleoside analogs,
non-nucleoside analogs and anti-sense oligonucleotides (ASO). The
family of nucleoside analogs consists of members with a modiﬁed
cytidine, namely: 5-aza-cytidine, 5-aza-2-deoxycytidine, 5-ﬂuoro-2-
deoxycytidine and zebularine. These drugs, when incorporated into
DNA, formulate covalent bonds with DNMTs and block their enzymatic
activity. 5-aza-cytidine and 5-aza-2-deoxycytidine have been approved
by the Food and Drug Administration (FDA) for use in myelodysplastic
syndromes [80–82]. Non-nucleoside analogs, such as the small molecu-
lar inhibitor RG108 and ASO, such as MG98 inhibit DNMTs without
incorporation into DNA. 5-aza-2-deoxycytidine seems to function as a
Table 1
Clinical trials of agents that target epigenetic modiﬁcations.
Agent Disease Phase Result References
Nucleoside analog DNMTi




5-aza-2-deoxycytidine (decitabine) in combination with
carboplatin
Advanced solid tumors (pre-treated) I 35 enrolled patients [86]
7 CRC patients
1 partial response and 1 stable disease but
not in CRC
Establishment of dose that can be safely
combined with carboplatin
Anti-sense oligonucleotide DNMTi
MG98 Advanced solid tumors I 34 enrolled patients [87]
7 CRC patients
1 partial response and 1 prolonged stable





acid, SAHA) in combination with bortezomib
Advanced solid tumors I 29 enrolled patients [89]
3 CRC patients




Vorinostat in combination with 5-FU Refractory metastatic CRC II′ 58 enrolled patients [90]
1 partial response
Some disease stabilizations
Failure of reaching the prespeciﬁed
2 month PFS rate
Well-tolerated
Vorinostat in combination with 5-FU Pre-treated metastatic CRC I/II 10 patients enrolled [91]
2 stable disease
Failure of MTD establishment
Poor tolerability
Phenylbutyrate in combination with 5-FU Pre-treated metastatic CRC I 9 enrolled patients [92]
3 stable disease
Fairly tolerated
Valproic acid in combination with epirubicin Advanced solid malignancies I 48 enrolled patients [93]
2 CRC patients
9 partial responses
16 stable disease/minor responses
Well-tolerated
HDACi—cylic peptide
Romidepsin (Depsipeptide, FK228) Pre-treated advanced CRC II 28 enrolled patients [94]
4 stable disease
Ineffective at this dose for metastatic CRC
No signiﬁcant side-effects
HDACi—hydroxamic acids
Panobinostat (LBH589) in combination with bevacizumab
and everolimus
Advanced solid tumors heavily pre-treated I 12 enrolled patients [95]
9 CRC patients
1 partial response (breast)
3 disease stabilization
(CRC)
No proof of HDAC inhibition
Not acceptable tolerability proﬁle
Belinostat (PXD101) in combination with carboplatin
and/or paclitaxel
Advanced solid malignancies I 23 enrolled patients [96]
2 rectal patients
2 partial responses (1 rectal)
Well-tolerated
HDACi—benzenamides
Mocetinostat (MGCD0103) Advanced solid tumors I 38 enrolled patients [97]
9 CRC patients
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Table 1 (continued)
Agent Disease Phase Result References
Entinostat (MS275,SNDX275) in combination with
13-cis retinoic acid





Pracinostat (SB939) Advanced solid tumors I 39 enrolled patients [99]
15 CRC
10 stable disease
3 patients with stable CRC N 6 months
Well-tolerated
Abbreviations: 5-FU, ﬂuorouracil; CRC, colorectal cancer; DNMT, DNA methyltransferase; DNMTi, DNMT inhibitor; HDAC, histone deacetylase; HDACi, HDAC inhibitor; MTD, maximum
tolerated dose; PFS, progression-free survival.
HDACi—benzenamides
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due to promoter hypermethylation but also facilitates the expression of
unmethylated genes, including those involved in apoptotic pathways
[83]. Recent experimental data demonstrated that the sole application
of DNMTi may be inadequate to reactivate gene expression. Instead, the
concomitant use of HDACi may function synergistically and re-enable
aberrantly silenced tumor suppressors [84]. Clinical application of
DNMTi in patients with various solid tumors has not yielded very
encouraging results. Most studies did not meet pre-speciﬁed endpoints
and the best clinical outcomewas usually disease stabilization (Table 1)
[85–87].
9.1.2. HDAC inhibitors
Due to their involvement in multiple aspects of carcinogenesis,
HDACs reasonably are regarded as appealing targets in the ﬁght against
cancer. HDACi have shown a preferential efﬁcacy against hematological
malignancies and therefore vorinostat (SAHA) and romidepsin (FK228)
have gained FDA approval. Data regarding solid tumors however are not
so convincing and encouraging [30,80,88]. Results from most clinical
trials indicate that these agents are not particularly efﬁcient against
solid tumors, whereas their tolerability proﬁle is fairly favorable
(Table 1) [89–99]. Possible side-effects and the limited clinical efﬁcacy
may result from the inability of HDACi to act as selective inhibitors [88].
In this direction, various groups attempt to generate speciﬁc inhibitors.
In vitro data demonstrated that a small molecular inhibitor of HDAC6
was able to promote apoptosis and block cell proliferation in CRC xeno-
graft models [100].
9.1.3. Other therapeutic approaches
In contrast to DNMTi and HDACi, the application of agents interven-
ing in histone methylation, HATs, chromatin remodelers andmiR is still
at primitive level [81]. Targeting of HMTs has been reported to inhibit
the migrating potential of CRC cells and to facilitate apoptosis in colon
CSCs [41,101]. Intriguingly, statins, a class of cholesterol-reducing
drugs, seem to lower CRC risk and could be used as putative anti-
cancer agents. Novel ﬁndings have shed light on their mechanism of
action, suggesting an interaction with the epigenetic machinery. It has
been demonstrated that statins, possibly through EZH2 inhibition,
suppress proliferation and induce growth arrest of CRC cells, while
their anti-cancer efﬁcacy was further sustained when co-administered
with HDACi [102]. Recent experimental data also suggest that statins
exert their tumor-protecting effects by forcing CRC cells to shift into a
mature phenotype and thus facilitating chemo-sensitization through
demethylation of the promoter of the gene encoding bone morphoge-
netic protein (BMP) 2 [103]. The application of LSD1 inhibitors in CRC
cell lines has produced encouraging results as it reactivated commonly
silenced tumor suppressor genes [104]. Small molecular HAT inhibitors
have been shown to ask cytotoxic effects upon CRC cells, with a favor-
able pharmacokinetic proﬁle [105]. Additionally, modulation of chro-
matin remodeling may be achieved via pharmacological inhibition of
each individual members of a given complex [30].Radiation therapy, which has been used for the treatment of rectal
cancers, seems to affect epigenetic patterns. Radiation could cause a
state of genetic instability and promote apoptosis in cancer cells
through inhibition of DNMTs and alterations in histone modiﬁcations
and miR expression proﬁles [19].
Finally, miRs are regarded as alternative rational targets. In general
re-activation of miRs bearing tumor-suppressive potential can be
achieved through treatment with a DNMTi, an oligonucleotide mimic
or a miR expression vector [69,106]. On the other hand silencing of
oncogenic miR is achieved via the application of ASOs [67]. For instance,
restoration of miR-212, miR-145 and miR-33a in CRC cell lines and
xenograft models has been shown to induce growth arrest [69,106],
whereas silencing of miR-21 in CRC cell lines induced differentiation
and chemosensitization [67].
9.2. Natural compounds
Natural compounds modulate epigenetic modiﬁcations in a multi-
level manner. Numerous dietary factors including, folate, vitamins, epi-
gallocatechin 3-gallate (EGCG) from green tea, genistein from soybean,
catechol-containing coffee polyphenols and ﬂavonoids alter the avail-
ability of methyl groups, inﬂuence the activity of DNMTs and control
DNA methylation and histone acetylation [82]. Evidence from a recent
study indicates that genistein could ask its protective effects by altering
DNAmethylation and histone modiﬁcations. Indeed genistein is able to
keepWnt pathwaymembers in normal levels in colonic epithelia of rat
models after exposure to carcinogens [107]. Curcumin, the biologically
active ingredient of the spice turmeric, is another putative chemopre-
ventive agent due to its modulatory actions in numerous cellularmech-
anisms, including DNA methylation. Moreover it seems that curcumin
functions in vitro as a speciﬁc DNMTi [108]. In a phase I study, the admin-
istration of freeze-dried black raspberries in CRC patients altered the
expression of genes involved in cell proliferation, angiogenesis and
apoptosis through the inhibition inhibition of DNMT1, which led to
the hypomethylation of various tumor-suppressor genes [109]. Green
tea extracts are regarded as promising cancer preventing agents. Cur-
rently another clinical study has focused on determining the beneﬁcial
effects of green tea (EGCG) on minimizing the risk of metachronous
adenomas and thus CRC [110].
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